OncRef

Clinical Trial: NCT03113643

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:Dana-Farber Cancer Institute
Information Provided By:Dana-Farber Cancer Institute
Last Update Posted:2026-06-17

Study Overview

Brief Summary

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS.

The interventions involved in this study are:

  • SL-401
  • Azacitidine
  • Venetoclax

Official Title

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)

Conditions

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm

Intervention / Treatment

  • Drug: Azacitidine
  • Drug: SL-401
  • Drug: Venetoclax

Other Study ID Numbers

  • 17-056

Start Date (Actual)

2017-06-26

Primary Completion Date (Actual)

2021-09-15

Study Completion Date (Estimated)

2027-05-31

Enrollment (Estimated)

72

Study Type

Interventional

Phase

Phase 1